Table 1.

NOS Catalytic Activity of Cell Homogenates or Intact B-CLL Cells

B-CLL No. Treatment NOS Activity (pmol/min/mg) A/Cell Homogenates
1  No  27 ± 4  
 IgG1 22 ± 5  
 Anti-CD23  52 ± 8  
2  No 18 ± 3  
 IgG1 22 ± 6 
 Anti-CD23  56 ± 11 
  NOS Activity (pmol/106 cells) B/Intact Cells  
 
3  No 1.0 ± 0.4  
 IgG1 1.9 ± 0.5 
 Anti-CD23  6.7 ± 1.1  
4  No  1.2 ± 0.4 
 IgG1 0.2 ± 0.2  
 Anti-CD23 5.6 ± 1.2  
5  No  2.4 ± 0.6 
 IgG1 1.0 ± 0.4  
 Anti-CD23 9.0 ± 2.2  
6  No  0.6 ± 0.3 
 IgG1 0.6 ± 0.5  
 Anti-CD23 7.5 ± 1.4 
B-CLL No. Treatment NOS Activity (pmol/min/mg) A/Cell Homogenates
1  No  27 ± 4  
 IgG1 22 ± 5  
 Anti-CD23  52 ± 8  
2  No 18 ± 3  
 IgG1 22 ± 6 
 Anti-CD23  56 ± 11 
  NOS Activity (pmol/106 cells) B/Intact Cells  
 
3  No 1.0 ± 0.4  
 IgG1 1.9 ± 0.5 
 Anti-CD23  6.7 ± 1.1  
4  No  1.2 ± 0.4 
 IgG1 0.2 ± 0.2  
 Anti-CD23 5.6 ± 1.2  
5  No  2.4 ± 0.6 
 IgG1 1.0 ± 0.4  
 Anti-CD23 9.0 ± 2.2  
6  No  0.6 ± 0.3 
 IgG1 0.6 ± 0.5  
 Anti-CD23 7.5 ± 1.4 

The NOS activity of six different B-CLL cell samples was determined by measuring, in duplicate, the conversion of14C-L-arginine into 14C-L-citrulline, either by cell lysates for two of them (A) or by intact cells for the other four cases (B). B-CLL cells were incubated overnight in medium alone or containing 10 μg/mL of anti-CD23 MoAb or control IgG1. Cell homogenates (A) were prepared at the end of the incubation time and their NOS enzymatic activity was tested over a 30-minute period. Alternatively, radiolabeled arginine was added at the beginning of the culture and the formation of radiolabeled citrulline in cell-free supernatants (B) was estimated at the end of the culture. Results (mean ± SD of duplicate samples) are expressed either in pmol/min/mg or pmol/106 cells.

or Create an Account

Close Modal
Close Modal